Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brolucizumab - Novartis

Next Previous
Drug Profile

Brolucizumab - Novartis

Alternative Names: Beobyu; BEOVU; Beovu; Brolucizumab-dbll; ESBA-1008; RTH-258

Latest Information Update: 18 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ESBATech
  • Developer Novartis
  • Class Antibodies; Eye disorder therapies; Immunoglobulin Fv fragments; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Wet age-related macular degeneration
  • Registered Diabetic macular oedema
  • Phase III Diabetic retinopathy; Polypoidal choroidal vasculopathy; Retinal vein occlusion

Most Recent Events

  • 19 Jun 2024 Novartis Pharmaceuticals completes the phase III CONDOR trial in Diabetic retinopathy in Argentina, USA, Australia, Brazil, Canada, Chile, China, India, Japan, South Korea, Mexico, Philippines, Puerto Rico, Russia, Turkey, Taiwan (Intravitreous) (NCT04278417)
  • 27 Mar 2024 Pyxis Oncology sells the rights to royalties from the commercialization of brolucizumab to Novartis
  • 28 Feb 2024 Novartis completes the phase III trial in Wet age-related macular degeneration (Treatment-naive) in China (Intravitreous) (NCT04047472)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top